Jump to content

Search the Community

Showing results for tags 'Insilico Medicine'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Forums
    • CR Science & Theory
    • CR Practice
    • Chitchat
    • General Health and Longevity
    • CR Recipes
    • Members-Only Area
  • Community

Blogs

  • Paul McGlothin's Blog
  • News
  • Calorie Restriction News Update

Categories

  • Supporting Members Only
  • Recipes
  • Research

Product Groups

  • CR IX
  • CRSI Membership
  • Conference DVDs

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Website URL

Found 1 result

  1. All, Sthira has several times (e.g. here) plaintively called for the more widespread application of advances in the burgeoning field of artificial intelligence to the problem of defeating aging. You would think Google-owned Calico would be leading the charge in the arena, and perhaps they are. But Calico's inner workings are quite opaque, and judging by the apparent vaporware status of the glucose-monitoring contact lenses supposedly under development at Verily, that other Google-owned, health technology-focused company, we may be waiting a long time for results from Calico... Fortunately, it appears others in the tech industry are picking up the torch of applying AI to the problem of aging. This announcement talks about a partnership between the Life Extension Foundation (LEF) and Insilico Medicine, a Big Data / AI startup that was spun off from Johns Hopkins University that is focused on applying deep learning to drug discovery. According to the press release, the partnership will focus on discovering "effective nutraceuticals that promote the young healthy state in old tissues and support health and longevity." In a bit more detail: Insilico Medicine will focus on applying advanced signaling pathway activation analysis techniques and deep learning algorithms to find nutraceuticals that mimic the tissue-specific transcriptional response of many known interventions and pathways associated with health and longevity. They will also search for dietary ingredients referred to as "geroprotectors" that mimic the young healthy signaling state in older human tissues. Life Extension will use this information to develop novel nutraceutical products to support health and longevity. While I'm not very optimistic about the prospects of dramatic life extension via pharmacological interventions, it's good to see AI, Big Data and deep learning being applied to "advanced signaling pathway activation analysis". It seems to me that any true longevity breakthrough will require this sort of analysis to help unravel the incredible complexity of human metabolism as it relates to aging, whether it can ultimately be translated into "geroprotector" nutraceuticals or (more likely) not. --Dean
×